Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.

Response rates of epidermal growth factor receptor ( This multicenter, retrospective study included patients with Of the 22 patients studied [males =8 and females =14; Eastern Cooperative Oncology Group (ECOG) 1 or 2 =7 and ECOG 3 or 4 =15], 45.5% were on 40 mg OD, 31.8% were on 80 mg every other day (EOD), and 22.7% on 40 mg EOD. First-line EGFR TKIs used included afatinib, erlotinib, and gefitinib. The ORR with lower doses of second-line osimertinib was 77.3%. Overall, the median PFS was 10.0 months [95% confidence interval (CI): 8.6-11.4] and median OS was 13.0 months (95% CI: 9.4-16.6). In patients with ECOG 1 or 2, the median PFS was 18.0 months (95% CI: 5.8-30.2) and the median OS was not reached at the time of analysis. In patients with poor ECOG performance status of 3 and 4, good survival outcomes were also seen with a median PFS of 7.0 months (95% CI: 4.7-9.3) and median OS of 10.0 months (95% CI: 7.5-12.5). All AEs except one case of paronychia were Grade 1. There were no Grade 3 or 4 AEs. Treatment with low dose osimertinib demonstrated good efficacy and tolerability in

2024 Translational Lung Cancer Research. All rights reserved.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-243/coif). M.E.P. received honoraria and fees for lectures from AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer and Roche. S.B. received honoraria for a talk from Menarini. C.K.L. received research grants from AstraZeneca and Boehringer Ingelheim; received honoraria and fees for lectures and advisory board meetings from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Merck, MSD, Novartis, Pfizer, Roche and Zuellig Pharma. J.L.T. received honoraria for lecture/presentation from Boehringer Ingelheim, Eli Lilly, MSD, and Pfizer; received support to attend the World Conference on Lung Cancer 2023 from MSD; and participated in the Advisory Board for Neoadjuvant Immunotherapy for Bristol Myers Squibb. L.M.T. is the President of the Lung Cancer Network Malaysia; received honoraria from AstraZeneca, Eisai, Ipsen, Janssen, MSD, Novartis, Pfizer, and Roche; and received support for attending meetings from AstraZeneca, MSD, and Roche. S.H.H. received clinical trial grants to his institution from AstraZeneca, Boehringer Ingelheim, Janssen, MSD, Novartis, and Roche; received payment for attending Advisory Board meetings from AstraZeneca, Janssen, MSD, and Roche; received payment for publication of clinical trial results from AstraZeneca and Janssen; and received support to attend the World Conference on Lung Cancer 2023 from MSD. The other authors have no conflicts of interest to declare.